Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC, which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
The new manufacturing process is expected to significantly enhance Regentis’ ability to meet anticipated demand for GelrinC in Europe and beyond. By increasing yield and improving efficiency, the company can scale production while reducing costs and environmental impact. This is particularly important given that GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process.
For more information about Regentis and its news, visit the company’s newsroom at https://ibn.fm/RGNT. The full press release is available at https://ibn.fm/Ths4h.
This approval marks a critical step toward bringing GelrinC to patients, potentially transforming the treatment of cartilage injuries and osteoarthritis. With a U.S. market worth $3 billion and no off-the-shelf alternative, GelrinC could fill a significant unmet medical need if it receives FDA approval. The improved manufacturing process not only boosts supply capacity but also enhances safety for workers and the environment, aligning with broader industry trends toward sustainable production.
